Early intensification of glucose-lowering therapy: VERIFY lessons and real clinical practice on the example of the Moscow region diabetes register data

BACKGROUND: The prevalence of T2DM is steadily increasing not only among the elderly, but also at a young age. T2DM is preceded by a long period of significant metabolic changes with the development of insulin resistance and в-cell dysfunction. To reduce the prevalence of complications, treatment is needed which affects several pathophysiological mechanisms underlying the disease. Monotherapy with metformin at the onset of T2DM is often insufficient. The VERIFY study demonstrated the advantage of early administration of a combination of vildagliptin and metformin in relation to the glycemic durability compared to the sequential intensification of metformin with vildagliptin in patients with type 2 diabetes.
AIMS: To assess the current situation in terms of the incidence of T2DM complications and the structure of the prescribing glucose lowering drugs based on the data from the Diabetes Register (DR) of the Moscow Region. To demonstrate the advantages of early combination therapy in patients with newly diagnosed T2DM using clinical cases.
MATERIALS AND METHODS: The data from the DR of the Moscow region, which is part of the National Diabetes Register of the Russian Federation, were used for the analysis. The data of 6,096 patients with T2DM who died in 2019 were evaluated for building the structure of the causes of death of patients with T2DM. The pattern of glucose-lowering therapy was analyzed based on data of 226,327 patients with T2DM (for 2020), as well as separately of 14,379 patients with newly diagnosed T2DM in 2019. Clinical cases are described based on the data of two patients with T2DM, available in the DR database and outpatient records.
RESULTS: In patients with young onset T2DM (<40 years), the prevalence of severe complications is higher than in the general population of patients with T2DM: blindness is in 5.9 times, end-stage chronic renal failure in 2.9 times, lower limb amputations in 6.4 times more. When prescribing glucose lowering drugs, monotherapy is prevalent, mostly metformin. In double combination, metformin is used in 96.22% of cases. In the structure of glucose lowering drugs, with newly diagnosed T2DM, combination therapy is used less frequently than in patients with T2DM in general. Of the drugs of the IDP-4 group, vildagliptin is most often prescribed — 46.25% (including of a fixed combination with metformin — 12.22%). Clinical cases reflect a rapid clinical outcome: a decrease in HbA1c to the target in 6 months, the absence of hypoglycemia or other side effects, and positive weight dynamics.
CONCLUSIONS: A fairly large propotion of patients with T2DM are on monotherapy with glucouse lowering drugs. Early prescription of the combination of metformin plus vildagliptin provides a longer maintenance of glycemic control without increasing the risk of hypoglycemia and weight gain for patients with newly diagnosed T2DM.

1. Varghese RT, Dalla Man C, Sharma A, et al. Mechanisms Underlying the Pathogenesis of Isolated Impaired Glucose Tolerance in Humans. J Clin Endocrinol Metab. 2016;101(12):4816-4824. doi: https://doi.org/10.1210/jc.2016-1998

2. Tentolouris N, Eleftheriadou I. Diabetes mellitus doubles the risk of type 2 cardiorenal syndrome: results from the NHANES trial. Hell J Cardiol. 2017;58(5):348-349. doi: https://doi.org/10.1016/j.hjc.2017.11.013

3. Arnold SV, Kosiborod M, Wang J, et al. Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. Diabetes, Obes Metab. 2018;20(8):2000-2003. doi: https://doi.org/10.1111/dom.13303

4. Bailey CJ, Day C. Treatment of type 2 diabetes: future approaches. Br Med Bull. 2018;126(1):123-137.

5. Шестакова Е.А. Возможности ранней комбинированной терапии сахарного диабета 2-го типа // Проблемы эндокринологии. 2015. — Т. 51. — №5. — С. 56-59. doi: https://doi.org/10.14341/probl201561556-59

6. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS). Group UKPDS 34. Lancet. 1998;352:854-865; 352:837-853.

7. Saisho Y. Changing the Concept of Type 2 Diabetes: Beta Cell Workload Hypothesis Revisited. Endocrine, Metab Immune Disord — Drug Targets. 2019;19(2):121-127. doi: https://doi.org/10.2174/1871530318666180821161825

8. Lyu X, Zhu X, Zhao B, et al. Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: metaanalysis of randomized controlled trials. Sci Rep. 2017;7(1):44865. doi: https://doi.org/10.1038/srep44865

9. Pratley RE, Schweizer A, Rosenstock J, et al. Robust improvements in fasting and prandial measures of p-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obes Metab. 2008;10(10):931-938. doi: https://doi.org/10.1111/j.1463-1326.2007.00835.x

10. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 9-й выпуск (дополненный) // Сахарный диабет. — 2019 — Т. 22. — № 151. — С. 1-144. doi: https://doi.org/10.14341/DM221S1

11. Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020;63(2):221-228. doi: https://doi.org/10.1007/s00125-019-05039-w

12. Matthews DR, Paldanius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519-1529. doi: https://doi.org/10.1016/S0140-6736(19)32131-2

13. Paldanius PM, Ivaska KK, Hovi P, et al. Poster presented at 56 Virtual Annual Meeting EASD; 2020; Sep 21-25.

14. Lebovitz H. Importance of early insulin secretion. Diabetes rev. 1999;7:139-153.

15. Rombopoulos G, Hatzikou M, Athanasiadis A, Elisaf M. Treatment Compliance with Fixed-Dose Combination of Vildagliptin/Metformin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy: A 24-Week Observational Study. Int J Endocrinol. 2015;2015(11):1-5. doi: https://doi.org/10.1155/2015/251485

16. Сунцов Ю.И., Болотская Л.Л., Маслова О.В., и др. Эпидемиология сахарного диабета и прогноз его распространенности в Российской Федерации // Сахарный диабет. — 2011. — №1. — С. 15-18.

17. Huang D, Refaat M, Mohammedi K, et al. Macrovascular Complications in Patients with Diabetes and Prediabetes. Biomed Res Int. 2017;2017:1-9. doi: https://doi.org/10.1155/2017/7839101

18. Sattar N, Rawshani A, Franzen S, et al. Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks. Circulation. 2019;139(19):2228-2237. doi: https://doi.org/10.1161/CIRCULATIONAHA.118.037885

19. Liatis S, Dafoulas GE, Kani C, et al. The prevalence and treatment patterns of diabetes in the Greek population based on real-world data from the nation-wide prescription database. Diabetes Res Clin Pract. 2016;118:162-167. doi: https://doi.org/10.1016/j.diabres.2016.06.018

20. Kim J, Park S, Kim H, Je NK. National trends in metformin-based combination therapy of oral hypoglycaemic agents for type 2 diabetes mellitus. Eur J Clin Pharmacol. 2019;75(12):1723-1730. doi: https://doi.org/10.1007/s00228-019-02751-9

21. Wilkinson S, Douglas I, Stirnadel-Farrant H, et al. Changing use of antidiabetic drugs in the UK: trends in prescribing 2000-2017. BMJ Open. 2018;8(7):e022768. doi: https://doi.org/10.1136/bmjopen-2018-022768.